Alkermes plc. Deferred Federal Income Tax Expense (Benefit)
Alkermes plc. (ALKS) reported Deferred Federal Income Tax Expense (Benefit) of -$19.87 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2025-02-12
- Alkermes plc. deferred federal income tax expense (benefit) for fiscal 2024 was -$19.87M, a 294.96% decline from fiscal 2023.
- Alkermes plc. deferred federal income tax expense (benefit) for fiscal 2023 was $10.19M.
- Alkermes plc. deferred federal income tax expense (benefit) for fiscal 2022 was -$10.54M, a 212.42% decline from fiscal 2021.
- Alkermes plc. deferred federal income tax expense (benefit) for fiscal 2021 was $9.37M, a 5.10% decline from fiscal 2020.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$19.87M 10-K · filed 2025-02-12 | |
| 2023-12-31 | $10.19M 10-K · filed 2025-02-12 | |
| 2022-12-31 | -$10.54M 10-K · filed 2025-02-12 | -$28.12M 10-K · filed 2023-02-16 |
| 2021-12-31 | $9.37M 10-K · filed 2024-02-21 | $5.91M 10-K · filed 2022-02-16 |
| 2020-12-31 | $9.88M 10-K · filed 2023-02-16 | |
| 2019-12-31 | -$1.50M 10-K · filed 2022-02-16 | |
| 2018-12-31 | $10.62M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |